Detalles de la búsqueda
1.
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.
Mol Psychiatry
; 25(11): 2786-2799, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30116027
2.
Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu3 NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy.
Bioorg Med Chem Lett
; 29(18): 2670-2674, 2019 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31358468
3.
VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate.
Bioorg Med Chem Lett
; 29(14): 1714-1718, 2019 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31113706
4.
Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.
Brain
; 139(Pt 5): 1325-47, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27189581
5.
Oral Ingestion and Intraventricular Injection of Curcumin Attenuates the Effort-Related Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Motivational Symptoms of Depression.
J Nat Prod
; 80(10): 2839-2844, 2017 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28905625
6.
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.
J Neurosci
; 33(49): 19120-30, 2013 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24305809
7.
Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms.
Int J Neuropsychopharmacol
; 18(2)2014 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25575584
8.
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Biol Psychiatry
; 2024 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537670
9.
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
Am J Psychiatry
; 179(9): 611-627, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35758639
10.
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Trends Pharmacol Sci
; 43(12): 1098-1112, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273943
11.
Sex differences in effort-related decision-making: role of dopamine D2 receptor antagonism.
Psychopharmacology (Berl)
; 238(6): 1609-1619, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33590311
12.
Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent Models.
ACS Chem Neurosci
; 10(1): 33-35, 2019 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30346132
13.
Shared Behavioral and Neurocircuitry Disruptions in Drug Addiction, Obesity, and Binge Eating Disorder: Focus on Group I mGluRs in the Mesolimbic Dopamine Pathway.
ACS Chem Neurosci
; 10(5): 2125-2143, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30933466
14.
Chronic corticosterone administration induces negative valence and impairs positive valence behaviors in mice.
Transl Psychiatry
; 9(1): 337, 2019 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31822658
15.
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).
J Med Chem
; 62(3): 1690-1695, 2019 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30608678
16.
Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.
Neuropharmacology
; 136(Pt C): 438-448, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28893562
17.
The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions.
Behav Brain Res
; 342: 27-34, 2018 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29292157
18.
Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.
Pharmacol Biochem Behav
; 166: 13-20, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29309800
19.
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.
Neuropsychopharmacology
; 43(10): 2056-2063, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925886
20.
Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.
Psychopharmacology (Berl)
; 234(9-10): 1525-1534, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28083675